Tag: Press Release
Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline
LOS ANGELES–(BUSINESS WIRE)–Qnovia, Inc. (Qnovia), a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases, today announced it has raised $17 million in Series A funding. The financing was led by Blue Ledge Capital and included DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures.
“We are excited by the possibilities that exist beyond NRT for this innovative new drug platform and look forward to supporting them on this journey.”
“This Series A closing represents a major milestone for Qnovia as we seek to develop an initial proof of concept for our platform in NRT before expanding into additional therapeutic indications,” said Brian Quigley, CEO of Qnovia. “Once the FDA approves our Investigational New Drug (IND) application, we plan to initiate a Phase 1 study for NRT in 2023. As we pursue NRT authorization, we aim to identify significant expansion indications to pursue both alone and with partnerships.”
The Series A proceeds will be used by Qnovia to advance its NRT drug candidate through an IND submission with the FDA and begin human clinical trials in 2023.
“We are thrilled to be backing this new platform for inhaled therapeutics, and our participation in this round reflects not only our confidence in the technology but in Qnovia’s management’s ability to bring it to consumers and patients,” said Andy Roche, Founder and CIO at Blue Ledge Capital. “We are excited by the possibilities that exist beyond NRT for this innovative new drug platform and look forward to supporting them on this journey.”
About Qnovia, Inc.
Qnovia, Inc. is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. The company’s drug delivery platform, the RespiRx™, is the first orientation-agnostic, portable vibrating mesh nebulizer that effectively operates in any position held by the patient. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs. The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies. The company’s website can be found at www.qnovia.com.
Contacts
Investor Relations:
Qnovia, Inc.
kiki@gilmartinir.com
Media Relations:
Richard Laermer
CEO
RLM Public Relations
212-741-5106 X 216
Qnovia@RLMpr.com
Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name
LOS ANGELES–(BUSINESS WIRE)–Respira Technologies, Inc.—a clinical-stage company developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseases—has rebranded as “QNOVIA” and adopted Qnovia, Inc. as its corporate name. As part of the rebranding, the company has migrated to a new website (https://www.qnovia.com).
The company is advancing to an IND submission and is securing financing for human clinical trials. As the company advances, this rebranding will further differentiate the company’s technology and products from others in the biotechnology space.
This news follows the recent appointment of Brian Quigley as CEO of the company. Previously, Quigley served as COO. Quigley is a former executive at Altria Group, Inc., where he worked for 16 years. For seven of those years, Quigley served as President & CEO of Altria’s Smokeless and Innovative Products/Vapor Businesses. Quigley has over 15 years of business leadership experience in driving innovation and shareholder returns in regulated industries.
About Qnovia, Inc. (formerly Respira Technologies, Inc.)
Qnovia, Inc. is a health tech company focused on commercializing proprietary inhalation device technologies to improve patient outcomes. The company is currently engaged with FDA CDER to pursue a combination product authorization as the first inhalable prescription smoking cessation therapy.
The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.
The company’s key product, the RespiRx™ device, is the first orientation-agnostic, portable VMN device that effectively operates in any position held by the patient. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs with safe and effective inhalable drug delivery mechanisms that only the RespiRx™ device can deliver.
Qnovia, Inc. is backed by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, Poseidon Asset Management and TL Capital Group LLC.
Contacts
Investor Relations:
Qnovia, Inc.
kiki@gilmartinir.com
Media Relations Contact:
Richard Laermer
RLM PR
212-741-5106 X 216
Qnovia@RLMpr.com